January 2023 - TrueScripts Management Services, an innovative Prescription Benefits Management (PBM) company, has recently finalized a partnership with two leading pharmacogenomic (PGx) technology providers. Together, this partnership will serve to advance precision prescribing initiatives and deliver a more clinically sound Rx treatment plan to TrueScripts members.

FlexHealth is the pharmacogenomics laboratory division of Flexsus, LLC. The Company is centrally located in Columbus, Ohio, providing quality DNA testing across the United States to optimize medication program efficacy, safety, and adherence. FlexHealth has established a precision prescribing ecosystem that empowers health systems, pharmacists, and insurance providers by leveraging PGx test data to deliver actionable results that improve patient safety and employee wellness while reducing healthcare spend.

Combined with GenXys' best-in-class software platform, FlexHealth can perform PGx testing and use results to identify the most efficient and safe medications for individuals based on their genomic profile.

GenXys, the global leader in precision prescribing software with embedded PGx data, will provide evidence-based clinical guidance as a risk stratification tool for identifying those at high risk of Drug-Gene Interactions (DGI) within a member population. GenXys will also include patient health variables and interactions beyond PGx to provide absolute confidence in prescribing decisions.

Through the integration with FlexHealth and GenXys, TrueScripts’ PGx certified pharmacists and clinical staff can design Medication Action Plans (MAPs) to recommend the most appropriate therapy based on individual results. Additionally, TrueScripts can reference existing medication history in the clinical decision support process and enable providers to use PGx data automatically at the point of care. By incorporating these data points into the clinical workflow, TrueScripts is promoting better health outcomes for members with a targeted approach that will deliver maximum ROI for clients.

"As an intermediary, PBMs have an opportunity to help bridge gaps in patient care between the physician and pharmacist," says TrueScripts' Director of Clinical Programs and Compliance, Alan Kaffenberger, PharmD. "TrueScripts has always made an effort to do this, with a focus on and mantra of "right drug, right price, right time." Now, with the support of FlexHealth and GenXys and their advanced PGx technology, we can ramp up those efforts and provide an even stronger, more stable clinical offering for our members."



"This partnership is a significant step forward for GenXys and FlexHealth," says Karl Pringle, CEO of GenXys. "PGx is an important part of the prescribing puzzle and needs to be more widely included in prescribing decisions to offer personalized, safe, and appropriate medication options. When integrated into smart algorithms with other patient data points, leading companies like TrueScripts can offer proactive healthcare, deliver precision medicine to everyone, and level up healthcare inequality."

Auto-analysis of genetic information with other medication interaction points is helping to transform the "trial-and-error" approach of prescribing to one of precision and accuracy. TrueScripts is on a quest to improve healthcare as we know it. The partnership with GenXys and FlexHealth is an advancement of technological and medicinal integration that supports a better future of medicine for all.

TrueScripts clients and broker partners can expect to learn more on the PGx offering in Q2 2023.